Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on cancer, immune disorders, and viral diseases therapeutics, announced receiving a delisting notification from NYSE American on April 4, 2025. The Exchange suspended trading of AIM's common stock due to its low selling price, citing Section 1003(f)(v) of the NYSE American Company Guide.

The company plans to appeal the determination to the Exchange's Listing Qualifications Panel, though success is not guaranteed. Trading of AIM's common stock is expected to transition to the Pink Open Market starting April 7, 2025.

AIM ImmunoTech (NYSE: AIM) has reported its Q4 and full year 2024 financial results, highlighting progress in its Ampligen clinical development programs. The company ended 2024 with $4.0 million in cash and investments, down from $13.1 million in 2023. Financial metrics show reduced expenses, with R&D costs decreasing to $6.2 million from $10.9 million and G&A expenses dropping to $13.7 million from $21.1 million year-over-year.

Key developments include the advancement of the DURIPANC Phase 1b/2 trial combining Ampligen with AstraZeneca's Imfinzi for late-stage pancreatic cancer, and upcoming milestones in multiple clinical trials through 2026. The company is also pursuing studies in refractory melanoma, triple negative breast cancer, and advanced recurrent ovarian cancer, with several trials being partially funded by collaborators including AstraZeneca and Merck.

AIM ImmunoTech (NYSE American: AIM) participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference on March 11, 2025. CEO Thomas K. Equels presented five key focus areas for 2025:

• Progress in late-stage pancreatic cancer treatment through the Phase 1b/2 DURIPANC trial at Erasmus Medical Center, Netherlands
• Expanded research in ME/CFS and post-COVID conditions
• Advancement of oncology pipeline with trials reaching major milestones
• Development of Ampligen as a vaccine adjuvant for bird flu
• Ampligen's potential as a broad-spectrum immunotherapy

The presentation is available on-demand through the company's website and investor events page.

AIM ImmunoTech has announced that Dr. Paul Goepfert from the University of Alabama-Birmingham will lead a planned clinical study combining Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza, including avian influenza. This follows a previous UAB trial where Ampligen, used as a vaccine adjuvant, increased immune response to seasonal variants by over 4-fold and induced cross-reactive protection against highly pathogenic avian influenza strains H5N1, H7N9, and H7N3.

The company has engaged Amarex Clinical Research to prepare an Investigational New Drug application and manage the clinical study. AIM is seeking industry or governmental grants for study funding, with CEO Thomas K. Equels highlighting the potential cost-effectiveness of this approach at approximately $10 million in development costs compared to potentially billions for new mRNA vaccine development.

AIM ImmunoTech (NYSE American: AIM) has received acceptance from the NYSE American for its compliance plan to meet minimum stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the American Company Guide. The company has been granted until June 11, 2026 to regain compliance with the NYSE's Continued Listings Standards. CEO Thomas K. Equels expressed satisfaction with the approval and mentioned ongoing developments in the company's oncology and antiviral pipelines.

AIM ImmunoTech (NYSE American: AIM) has appointed David Chemerow as an Independent Director to its Board of Directors, effective immediately. Chemerow brings over 40 years of finance, accounting, and operations leadership experience to the role.

Chemerow previously served as CFO, Treasurer, and Chief Revenue Officer at Comscore, and as COO and CFO of Rentrak until its 2016 merger with Comscore. He currently serves on the Board of Directors for Dunham's Athleisure and the Advisory Board of Huntington Outdoor.

The appointment was unanimously approved by AIM's Board. Board Chairman William Mitchell highlighted Chemerow's proven track record of leadership and financial acumen as valuable additions to AIM's mission. Chemerow expressed optimism about AIM's position in the immuno-pharma space, particularly noting Ampligen's potential across various high-value indications.

AIM ImmunoTech (NYSE American: AIM) has dosed the first new subject in Phase 2 of their Phase 1b/2 clinical trial studying the combination of Ampligen (rintatolimod) and AstraZeneca's Imfinzi (durvalumab) for treating late-stage pancreatic cancer. The trial, known as DURIPANC, is being conducted at the Erasmus Medical Center in the Netherlands.

Several subjects from Phase 1 who received the highest dose will also be included in Phase 2. The investigator-initiated, exploratory, open-label, single-center study expects to enroll up to 25 patients in the Phase 2 portion.

AIM CEO Thomas K. Equels expressed confidence in steady enrollment, noting that unlike many pancreatic cancer studies where accrual can be challenging, they expect consistent patient recruitment for this trial combining the TLR-3 agonist rintatolimod with the anti-PD-L1 immune checkpoint inhibitor durvalumab.

AIM ImmunoTech (NYSE American: AIM) has released a Virtual Investor segment featuring CEO Thomas K. Equels and Professor Casper H.J. van Eijck from Erasmus Medical Center discussing their Phase 1b/2 clinical trial DURIPANC. The trial investigates the combination of AIM's Ampligen® and AstraZeneca's Imfinzi® for treating late-stage pancreatic cancer.

The Erasmus MC Safety Committee has approved advancing to Phase 2 after reviewing Phase 1 safety data, which showed the combination treatment was generally well-tolerated with no treatment-related severe adverse events or dose-limiting toxicities. The study is being conducted as an investigator-initiated, exploratory, open-label, single-center trial in the Netherlands at Erasmus MC.

AIM ImmunoTech (NYSE American: AIM) has announced it will postpone its planned offering under Registration Statement Form S-1. The company will not proceed with the offering until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.